We are live on ! Find out more
OXFD

Oxford Immunotec Global
OXFD

Delisted

OXFD was delisted on the 5th of March, 2021.

60 hedge funds and large institutions have $400M invested in Oxford Immunotec Global in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 21 increasing their positions, 28 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more capital inflows, than outflows

Capital inflows: $61.9M | Capital outflows: $37.9M

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

3.82% less ownership

Funds ownership: 92.14% → 88.32% (-3.8%)

15% less funds holding

Funds holding: 71 → 60 (-11)

25% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 28

83% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 12

Holders
60
Holders Change
-11
Holders Change %
-15.49%
% of All Funds
1.06%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
2
Increased
21
Reduced
28
Closed
12
Calls
$6​K
Puts
–
Net Calls
+$6​K
Net Calls Change
-⁠$5​K

OXFD Hedge Fund Activity: Q4 2020 in Review

60 of the 5,680 institutional investors tracked by Wall St. Rank reported a position in Oxford Immunotec Global (OXFD) for Q4 2020, worth a combined $400M — up 43% from $280M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of OXFD and 2 opened new positions — a net loss of 10 holders — while 28 trimmed existing stakes and 21 added.

The largest buyer was Endurant Capital Management, adding an estimated $6.82M. The largest seller was Alyeska Investment Group, cutting an estimated $10.7M.

  • 60 institutional investors held Oxford Immunotec Global (OXFD) as of Q4 2020, down from 71 in Q3 2020.
  • Funds reported $400M of Oxford Immunotec Global stock for Q4 2020, up 43% quarter-over-quarter.
  • 2 funds opened new Oxford Immunotec Global positions in Q4 2020 and 12 closed out, a net change of -10 holders.
  • The largest Oxford Immunotec Global buyer in Q4 2020 was Endurant Capital Management, an estimated $6.82M added.
  • The largest Oxford Immunotec Global seller in Q4 2020 was Alyeska Investment Group, an estimated $10.7M sold.

Based on aggregated 13F filings for Q4 2020.